COPD: DMP is largely consistent with guidelines

January 8, 2014

On 3 January 2014 the German Institute for Quality and Efficiency in Health Care (IQWiG) published the results of a literature search for evidence-based clinical practice guidelines on the treatment of people with chronic obstructive pulmonary disease (COPD). The aim of the report is to identify those recommendations from current guidelines of high methodological quality that may be relevant for the planned revision of the disease management programme (DMP). According to the results of the report, there is no compelling need for revision of any part of the DMP. However, IQWiG identified some aspects that could be supplemented and specified.

DMPs are revised regularly

After being commissioned by the Federal Joint Committee (G-BA), IQWiG systematically searched for new guidelines, assessed their , and extracted relevant recommendations from these guidelines. In a next step these recommendations were compared with the specifications for the German DMP.

A need for revision may arise if new studies provide new evidence on a disease and its treatment. It is therefore legally specified that a DMP must be revised at regular intervals. It is the Institute's responsibility to firstly identify differences between the guideline recommendations and the DMP. It is then the G-BA's responsibility to examine whether these differences should actually lead to a revision of the DMP.

13 relevant guidelines identified

IQWiG was able to include a total of 13 guidelines in its investigation. Four of these guidelines comprehensively address the care of patients with COPD. The others address specific aspects such as smoking cessation or refer to subgroups such as patients with alpha-1 antitrypsin deficiency, a congenital metabolic disorder.

Only few discrepancies

As IQWiG determined, the recommendations of the current guidelines are largely consistent with the requirements of the DMP; only few discrepancies were found. However, compared with the wording in the DMP directive, most recommendations are more detailed. For instance, the DMP directive states that patients should have access to a structured training programme. Several go one step further and also provide on what specific content should be conveyed in these programmes.

Procedure of report production

IQWiG published the preliminary results in the form of the preliminary report in May 2013 and interested parties were invited to submit comments. When the commenting procedure ended, the preliminary report was revised and sent as a final report to the commissioning agency, the Federal Joint Committee, in November 2013. The written comments submitted are published in a separate document at the same time as the final report. The report was produced in collaboration with external experts.

Explore further: DMP module on heart failure: Current guidelines indicate some need for revision

Related Stories

DMP module on heart failure: Current guidelines indicate some need for revision

August 1, 2012
The German Institute for Quality and Efficiency in Health Care (IQWiG) published the results of a literature search for evidence-based clinical practice guidelines on the treatment of people with heart failure. The aim of ...

DMP for diabetes type 2: Current guidelines indicate some need for revision

January 3, 2012
On 3 January 2012, the German Institute for Quality and Efficiency in Health Care (IQWiG) published the results of a literature search for evidence-based clinical practice guidelines on the treatment of people with diabetes ...

Obesity in type 2 diabetes: Recommendations from guidelines are largely consistent

July 30, 2012
On 10th July 2012, the German Institute for Quality and Efficiency in Health Care (IQWiG) published the results of a literature search for evidence-based guidelines for the treatment of obesity in type 2 diabetes. The aim ...

Guidelines on rare diseases: Methods on handling evidence neither identified nor required

April 28, 2011
People with rare diseases have the same right to high-quality health care in line with current medical knowledge as other patients do. However, relevant and reliable clinical studies on rare diseases are often lacking. Among ...

Benefit of PET or PET/CT in bone and soft tissue tumors is not proven

March 7, 2013
For patients with bone and soft tissue tumours, the study data currently available allow no robust conclusions as to the advantages and disadvantages of using positron emission tomography (PET), alone or in combination with ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.